Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.68%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.92%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.03%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.52%AUDUSD-1.45%AUDNZD-0.87%AUDCAD-0.87%EURAUD+0.87%AUDCHF-0.85%GBPAUD+0.80%GBPJPY-0.72%EURJPY-0.68%CHFJPY-0.67%NZDJPY-0.67%CADJPY-0.66%USDCHF+0.63%GBPUSD-0.63%USDCAD+0.59%EURUSD-0.59%NZDUSD-0.58%AUDSGD-0.50%USDZAR+0.45%AUDDKK-0.42%GBPTRY+0.41%USDTHB+0.36%AUDNOK-0.34%GBPHKD+0.32%EURZAR+0.30%NZDMXN+0.30%GBPMXN-0.28%USDMXN+0.28%GBPZAR+0.28%USDNOK+0.22%USDTRY+0.21%USDSEK+0.21%USDPLN+0.19%EURCNH-0.18%USDILS+0.16%USDDKK+0.15%EURHKD-0.15%CHFNOK+0.14%CHFSEK+0.12%USDCNH-0.11%NZDSGD+0.11%NOKJPY-0.10%USDJPY-0.09%GBPSGD-0.09%EURSGD-0.08%USDSGD+0.07%EURNOK+0.07%SGDJPY+0.06%GBPCAD-0.06%PLNJPY-0.06%EURSEK+0.06%GBPNZD-0.05%EURGBP+0.05%EURCHF+0.04%EURPLN+0.04%CADCHF+0.04%USDCOP-0.04%EURCZK+0.04%NZDCHF+0.03%EURNZD-0.02%CHFSGD-0.02%NZDCAD-0.01%EURCAD0.00%USDHKD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.62%XPTUSD-0.61%W1-0.42%C1-0.41%UKOIL+0.39%GAUUSD-0.32%XAUUSD-0.32%S1-0.23%XAGUSD-0.14%GAGUSD-0.14%COTTON+0.10%USOIL+0.07%BTCUSD-2.80%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+1.13%ZECUSDT-5.13%XMRUSDT-1.61%DOGEUSD+55.95%LINKUSD-2.46%XLMUSD-3.01%BCHUSDT-2.79%LTCUSD+47.50%UNIUSD-2.16%SUIUSD-1.92%TONUSD+59.18%HBARUSDT-4.33%TAOUSDT-1.85%AAVEUSD-2.60%ONDOUSDT-3.94%ICPUSDT-1.65%DOTUSDT-3.09%WLDUSDT-2.45%ARBUSDT-4.75%ATOMUSDT-1.71%INJUSDT-6.34%STXUSDT-0.96%PYTHUSDT+0.97%TIAUSDT-1.42%FETUSDT-3.75%JUPUSDT+2.15%SEIUSDT-2.00%GRTUSDT-2.58%OPUSDT-2.63%IOTAUSDT-1.19%POLUSDT-1.22%WIFUSDT-2.25%AXSUSDT-2.04%EOSUSDT-3.38%IMXUSDT-3.36%FARTCOINUSDT-5.08%GALAUSDT-1.65%DYDXUSDT-2.02%ORDIUSDT-1.49%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.68%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.92%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.03%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.52%AUDUSD-1.45%AUDNZD-0.87%AUDCAD-0.87%EURAUD+0.87%AUDCHF-0.85%GBPAUD+0.80%GBPJPY-0.72%EURJPY-0.68%CHFJPY-0.67%NZDJPY-0.67%CADJPY-0.66%USDCHF+0.63%GBPUSD-0.63%USDCAD+0.59%EURUSD-0.59%NZDUSD-0.58%AUDSGD-0.50%USDZAR+0.45%AUDDKK-0.42%GBPTRY+0.41%USDTHB+0.36%AUDNOK-0.34%GBPHKD+0.32%EURZAR+0.30%NZDMXN+0.30%GBPMXN-0.28%USDMXN+0.28%GBPZAR+0.28%USDNOK+0.22%USDTRY+0.21%USDSEK+0.21%USDPLN+0.19%EURCNH-0.18%USDILS+0.16%USDDKK+0.15%EURHKD-0.15%CHFNOK+0.14%CHFSEK+0.12%USDCNH-0.11%NZDSGD+0.11%NOKJPY-0.10%USDJPY-0.09%GBPSGD-0.09%EURSGD-0.08%USDSGD+0.07%EURNOK+0.07%SGDJPY+0.06%GBPCAD-0.06%PLNJPY-0.06%EURSEK+0.06%GBPNZD-0.05%EURGBP+0.05%EURCHF+0.04%EURPLN+0.04%CADCHF+0.04%USDCOP-0.04%EURCZK+0.04%NZDCHF+0.03%EURNZD-0.02%CHFSGD-0.02%NZDCAD-0.01%EURCAD0.00%USDHKD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.62%XPTUSD-0.61%W1-0.42%C1-0.41%UKOIL+0.39%GAUUSD-0.32%XAUUSD-0.32%S1-0.23%XAGUSD-0.14%GAGUSD-0.14%COTTON+0.10%USOIL+0.07%BTCUSD-2.80%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+1.13%ZECUSDT-5.13%XMRUSDT-1.61%DOGEUSD+55.95%LINKUSD-2.46%XLMUSD-3.01%BCHUSDT-2.79%LTCUSD+47.50%UNIUSD-2.16%SUIUSD-1.92%TONUSD+59.18%HBARUSDT-4.33%TAOUSDT-1.85%AAVEUSD-2.60%ONDOUSDT-3.94%ICPUSDT-1.65%DOTUSDT-3.09%WLDUSDT-2.45%ARBUSDT-4.75%ATOMUSDT-1.71%INJUSDT-6.34%STXUSDT-0.96%PYTHUSDT+0.97%TIAUSDT-1.42%FETUSDT-3.75%JUPUSDT+2.15%SEIUSDT-2.00%GRTUSDT-2.58%OPUSDT-2.63%IOTAUSDT-1.19%POLUSDT-1.22%WIFUSDT-2.25%AXSUSDT-2.04%EOSUSDT-3.38%IMXUSDT-3.36%FARTCOINUSDT-5.08%GALAUSDT-1.65%DYDXUSDT-2.02%ORDIUSDT-1.49%NOTUSDT+0.86%RONINUSDT-2.92%
VA

Vaxcyte, Inc. (PCVX)

NASDAQ • Healthcare

$58.52
-$0.87 (-1.5%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$59.16
Day Range$57.6 - $59.69
Avg. Volume (3M)1.7M
Market Cap$9.2B
52 Week Range
$42.4$90.75

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$1.1B
EPS (TTM)
-$8.07
ROA (TTM)
-38.42%
Current Ratio
4.56

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-29.4%Q2 2026-$2.3
+4.4%Q3 2026-$1.97
+5.7%Q4 2026-$1.99

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +5.7%

Vaxcyte’s loss per share topped consensus in the third fiscal quarter of 2026, based on preliminary results reported November 4, 2026, with EPS of -$1.99 topping the -$2.11 estimate by $0.12 even as the company remained in an investment-heavy clinical-stage phase around its vaccine pipeline, including VAX-24. Net income was a loss of roughly $297.1 million, down ~40% year over year from a loss of about $212.8 million, while EPS was -$1.99, down ~28% from -$1.56 a year ago. Operating income came in at a loss of about $308.3 million, reflecting ongoing R&D and operating spend typical for a development-stage biotechnology company without product revenue. Despite the net loss, Vaxcyte generated operating cash flow of about $56.5 million in the quarter. For the next period, consensus calls for EPS of -$2.06 on revenue of $12.5 million.

View full earnings history

About Vaxcyte, Inc.

Vaxcyte, Inc. trades on the NASDAQ as PCVX and operates in biotechnology within the healthcare sector. The company is a clinical development-stage vaccine maker that develops protein-based candidates to prevent or manage bacterial infectious diseases, rather than a commercial drug business with product revenue.

Name
Vaxcyte, Inc.
CEO
Grant E. Pickering
Industry
Healthcare
Year Founded
2013
Employees
507

Today's Snapshot

AI-generated

The day ended with PCVX 1.5% lower at 58.52, in line with a weaker sector. Vaxcyte said VAX-31, its adult vaccine, met pivotal trial goals.

Trading Volume

Below 10d avg (1.2M)

1.1M

vs S&P 500 Today

Underperforming Market

-1.22%

Updated: November 18, 2026 at 21:15 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
PCVX registers a sell bias as short- and medium-term averages sit above the current price while the 200-day average is slightly below, offering limited long-term support. Momentum indicators tilt bearish with a strongly negative CCI and a negative MACD, even as stochastic measures suggest short-term oversold conditions. Trend strength is modest and ADX is near the low-20s, while volatility is meaningful for the stock and on-balance volume does not confirm buying. The pivot is above the market and aligns with resistance. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$57.42 - $62.88
    Sell
  • RSI (14)41.66
    Neutral
  • Stochastic %K (14, 3, 3)11.07
    Buy
  • MACD Level (12, 26)-0.32
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.